Relmada urology CMO role ends September 3, 2026
RELMADA THERAPEUTICS, INC.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
RELMADA THERAPEUTICS, INC. (RLMD) reports that the employment of Dr. Raj S. Pruthi as Chief Medical Officer – Urology ended on September 3, 2026. The company filed this update as an other event and provided no additional detail about the circumstances around the end of his employment.
Insights
Analyzing...
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Employment end date: September 3, 2026
Trading symbol: RLMD
Form type: Form 8-K
3 metrics
Employment end date
September 3, 2026
Date Dr. Raj S. Pruthi’s role as Chief Medical Officer – Urology ended
Trading symbol
RLMD
Common stock listed on The NASDAQ Capital Market
Form type
Form 8-K
Current report disclosing end of Chief Medical Officer – Urology’s employment
Key Terms
Emerging growth company, The NASDAQ Capital Market, Section 12(b) of the Act
3 terms
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
The NASDAQ Capital Market market
"RLMD is listed on The NASDAQ Capital Market"
A tier of the Nasdaq stock exchange that hosts smaller or early-stage public companies that meet defined listing standards for size, share price and governance. Think of it as a particular shelf in a store for emerging brands: it gives investors a centralized place to find and trade these stocks while signaling that the companies meet basic regulatory and financial rules. Investors watch it for growth opportunities and higher volatility compared with larger markets.
Section 12(b) of the Act regulatory
"Securities registered pursuant to Section 12(b) of the Act"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What leadership change did RLMD announce on September 3, 2026?
Relmada Therapeutics disclosed that the employment of Dr. Raj S. Pruthi as Chief Medical Officer – Urology ended on September 3, 2026. The company reported this under an other events item and did not provide further explanatory details.
What position did Dr. Raj S. Pruthi hold at RLMD before his employment ended?
Dr. Raj S. Pruthi served as Chief Medical Officer – Urology at Relmada Therapeutics, Inc. before his employment with the company ended on September 3, 2026.
Does the RLMD 8-K describe why Dr. Pruthi’s employment ended?
No. The 8-K states only that Dr. Raj S. Pruthi’s employment as Chief Medical Officer – Urology ended on September 3, 2026. It does not describe the reasons or any terms related to the end of his employment.
Under what item did RLMD report the change involving Dr. Pruthi?
Relmada Therapeutics reported the end of Dr. Raj S. Pruthi’s employment under Item 8.01 – Other Events, indicating it as an informational disclosure rather than a specified governance or compensation item.
Who signed the RLMD 8-K reporting Dr. Pruthi’s employment ending?
The report was signed on behalf of Relmada Therapeutics, Inc. by Sergio Traversa, who is identified as the company’s Chief Executive Officer, dated September 8, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
